Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ionis Pharmaceuticals Inc.
Headquarters: Carlsbad, CA, United States of America
Website: http://www.ionispharma.com
Year Founded: 1989
Status: Public
Industry Sector: HealthTechnology
CEO: Brett P. Monia, PhD
Number Of Employees: 1,069
Enterprise Value: $4,882,871,440
PE Ratio: -9.39
Exchange/Ticker 1: NASDAQ:IONS
Exchange/Ticker 2: N/A
Latest Market Cap: $4,533,681,664
BioCentury | Mar 17, 2025
Deals
AZ acquires cell therapy play Esobiotech, Taiho acquires ADC partner Araris: Deals Report
Plus: Roche partners with Zealand, AZ with Alteogen and more
BioCentury | Feb 28, 2025
Product Development
Intellia: Balancing in vivo risk with validated targets
Sticking with genetic targets validated by Alnylam and Ionis gave Intellia confidence to take CRISPR in vivo
BioCentury | Feb 22, 2025
Discovery & Translation
Science Spotlight: Bacterial payload delivery from nose to brain
BioCentury’s roundup of translational innovations also includes targeting MSH3 to slow repeat expansion in Huntington’s; plus AAVs for kidney and T cells
BioCentury | Feb 20, 2025
Emerging Company Profile
Switch: Precision siRNA knockdown
San Francisco-based biotech is pursuing CNS diseases with three-stranded siRNAs that can target specific cell types within a tissue
BioCentury | Jan 22, 2025
Finance
Biotech bulls and bears in 2025
Public Markets Preview: Will political uncertainty resolve in biotech’s favor or lead to economically damaging policy?
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New modality showdowns
Genetic therapies compete in the same indications, as degraders come of age
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New mechanisms in obesity, neurology, ophthalmology
New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD
BioCentury | Jan 10, 2025
Data Byte
FDA’s new and supplemental approvals in December
Agency approves at least nine new therapies; adds new indications or patient populations to a dozen marketed drugs
BioCentury | Jan 6, 2025
Regulation
2024 Approvals: Where are the new modalities?
Last year’s new drug approvals by FDA reflect the continued focus on best-in-class drug development
BioCentury | Dec 20, 2024
Emerging Company Profile
City: Taking RNAi beyond the liver
Maraganore’s latest RNA company pairs targeting tech with trigger molecules a fraction of the size of Alnylam’s
Items per page:
1 - 10 of 459